Skip to content

Impact of ICP-Based Perioperative Monitoring and Management on Outcomes in Patients with Severe Aneurysmal Subarachnoid Hemorrhage: A Prospective, Multicenter, Cohort Study

Impact of ICP-Based Perioperative Monitoring and Management on Outcomes in Patients with Severe Aneurysmal Subarachnoid Hemorrhage: A Prospective, Multicenter, Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109837
Enrollment
Unknown
Registered
2025-09-25
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe aneurysmal subarachnoid hemorrhage

Interventions

ICPm Group (ventricular type):None
No-ICP group (simple external drainage):None

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Over 18 years old; 2. Diagnosis of subarachnoid hemorrhage caused by ruptured intracranial aneurysms through cranial CTA or DSA; 3. The Hunt-Hess grade at admission is greater than or equal to grade III; 4. Intracranial ruptured aneurysm occlusion (including interventional therapy or surgical treatment) should be performed within 24 hours after spider bleeding. 5. Patients who need to undergo intraventricular ICP implantation, external ventricular drainage tube (EVD) placement, ommaya implantation, or external lumbar cisterna drainage within 48 hours due to their condition for bloody cerebrospinal fluid drainage; 6. The patient's family members are aware of the research process and give informed consent.

Exclusion criteria

Exclusion criteria: 1. Exclude subarachnoid hemorrhage caused by other reasons, including trauma, arteriovenous malformations, venous malformations, coagulopathy and other subarachnoid hemorrhage not caused by aneurysm rupture (negative angiography); 2. Intracranial aneurysm rupture and hemorrhage caused by infectious diseases; 3. Patients with a Hunt-Hess score < grade III; 4. Patients with severe comorbidities within 6 months prior to the onset of this disease, such as malignant tumors, drug-resistant heart disease, coagulation disorders, or severe failure of other organ functions; 5. Patients with spider blood who refuse to have their disease management information collected and used and/or refuse to receive follow-up visits; 6. Pregnant or lactating women;

Design outcomes

Primary

MeasureTime frame
mRS Score (mRS>=4 is defined as a poor prognosis);

Secondary

MeasureTime frame
Complications;Daily treatment intensity;GCS score at discharge;In-hospital mortality;ICP value or drainage height per hour;

Countries

China

Contacts

Public ContactHu Jin

Huashan Hospital, Fudan University

hujin_dana@126.com+86 21 6564 2662

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026